Effect of Recombinant Human Brain Natriuretic Peptide on Ventricular Remodeling and Cardiac Function in Patients With Acute Anterior Myocardial Infraction Undergoing Percutaneous Coronary Intervention

Launched by THE FIRST AFFILIATED HOSPITAL WITH NANJING MEDICAL UNIVERSITY · Jun 16, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called Recombinant Human Brain Natriuretic Peptide (rhBNP) to see if it can help improve heart function and structure in patients who have experienced an acute anterior myocardial infarction (a type of heart attack) and are undergoing a procedure called percutaneous coronary intervention (PCI). The trial involves 100 participants who will be divided into two groups: one will receive rhBNP for three days after their procedure, while the other will receive a placebo (a treatment that has no active ingredients). Researchers will monitor various heart health indicators over a 24-week period to determine if rhBNP is effective and safe.

To participate, individuals must be between 18 and 75 years old and should be experiencing their first heart attack within 12 hours or have ongoing symptoms beyond that time. They must also be undergoing emergency PCI and successfully restore blood flow to the heart. However, certain individuals, such as those with severe heart conditions or specific medical histories, are not eligible for this study. Participants can expect regular check-ups and tests to assess their heart function during the trial, helping researchers gather important information about the potential benefits of rhBNP for heart health after a heart attack.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. The first acute anterior myocardial infarction ( AMI ) within 12 hours ( or more than 12 hours but the ischemic symptoms continue ).
• • 2. Age 18-75 years old, gender unlimited
• • 3. Patients with acute anterior myocardial infarction undergoing emergency PCI within the effective time window
• • 4. Successful reflow after interventional therapy ( TIMI = 3 ).
• • 5. To understand and sign the informed consent.
• • Exclusion Criteria：
• • 1. Patients with a history of coronary artery bypass grafting
• • 2. Patients with cardiogenic shock
• • 3. Patients with systolic blood pressure ( SBP ) ≤ 90 mmHg after treatment with vasopressors
• • 4. Patients with mechanical complications ( ventricular septal perforation, mitral chordae rupture )
• • 5. Patients with suspected aortic dissection
• • 6. Patients with severe liver and kidney dysfunction
• • 7. Allergic or intolerant to rhBNP.
• • 8. Patients with chronic renal insufficiency requiring long-term dialysis
• • 9. Patients using diuretics during the screening period
• • 10. Pregnant / lactating women
• • 11. Heart diseases that are not suitable for vasodilators, such as severe valve stenosis, restrictive cardiomyopathy, restrictive pericarditis, etc